Clinical Trial Update: Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating RAD001 (everolimus) in combination with carboplatin, paclitaxel, and bevacizumab in non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED